CN115698278B - 包含Cas12i2变体多肽的组合物及其用途 - Google Patents

包含Cas12i2变体多肽的组合物及其用途

Info

Publication number
CN115698278B
CN115698278B CN202180038904.1A CN202180038904A CN115698278B CN 115698278 B CN115698278 B CN 115698278B CN 202180038904 A CN202180038904 A CN 202180038904A CN 115698278 B CN115698278 B CN 115698278B
Authority
CN
China
Prior art keywords
variant
cas12i2
polypeptide
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180038904.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN115698278A (zh
Inventor
仲少荣
B·J·希尔伯特
Q·N·威塞尔斯
N·M·雅基莫
R·齐布拉特
J·M·卡特
T·M·迪托马索
J·R·哈斯威尔
A·J·加里蒂
C·A·麦格威
D·A·斯科特
D·M·切尔基奥内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Biotechnology
Original Assignee
Abbott Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotechnology filed Critical Abbott Biotechnology
Priority to CN202511379190.7A priority Critical patent/CN121380024A/zh
Publication of CN115698278A publication Critical patent/CN115698278A/zh
Application granted granted Critical
Publication of CN115698278B publication Critical patent/CN115698278B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180038904.1A 2020-03-31 2021-03-31 包含Cas12i2变体多肽的组合物及其用途 Active CN115698278B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511379190.7A CN121380024A (zh) 2020-03-31 2021-03-31 包含Cas12i2变体多肽的组合物及其用途

Applications Claiming Priority (37)

Application Number Priority Date Filing Date Title
US202063003064P 2020-03-31 2020-03-31
US202063003090P 2020-03-31 2020-03-31
US202063002999P 2020-03-31 2020-03-31
US63/002999 2020-03-31
US63/003090 2020-03-31
US63/003064 2020-03-31
US202063012007P 2020-04-17 2020-04-17
US63/012007 2020-04-17
US202063026562P 2020-05-18 2020-05-18
US202063026606P 2020-05-18 2020-05-18
US202063026523P 2020-05-18 2020-05-18
US202063026277P 2020-05-18 2020-05-18
US63/026606 2020-05-18
US63/026277 2020-05-18
US63/026562 2020-05-18
US63/026523 2020-05-18
US202063063879P 2020-08-10 2020-08-10
US202063063819P 2020-08-10 2020-08-10
US202063063831P 2020-08-10 2020-08-10
US202063063859P 2020-08-10 2020-08-10
US63/063879 2020-08-10
US63/063831 2020-08-10
US63/063819 2020-08-10
US63/063859 2020-08-10
US202063085752P 2020-09-30 2020-09-30
US202063085792P 2020-09-30 2020-09-30
US202063085895P 2020-09-30 2020-09-30
US202063085862P 2020-09-30 2020-09-30
US63/085895 2020-09-30
US63/085792 2020-09-30
US63/085752 2020-09-30
US63/085862 2020-09-30
US202163147850P 2021-02-10 2021-02-10
US202163147968P 2021-02-10 2021-02-10
US63/147968 2021-02-10
US63/147850 2021-02-10
PCT/US2021/025257 WO2021202800A1 (en) 2020-03-31 2021-03-31 Compositions comprising a cas12i2 variant polypeptide and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511379190.7A Division CN121380024A (zh) 2020-03-31 2021-03-31 包含Cas12i2变体多肽的组合物及其用途

Publications (2)

Publication Number Publication Date
CN115698278A CN115698278A (zh) 2023-02-03
CN115698278B true CN115698278B (zh) 2025-10-17

Family

ID=75640000

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180038904.1A Active CN115698278B (zh) 2020-03-31 2021-03-31 包含Cas12i2变体多肽的组合物及其用途
CN202511379190.7A Pending CN121380024A (zh) 2020-03-31 2021-03-31 包含Cas12i2变体多肽的组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511379190.7A Pending CN121380024A (zh) 2020-03-31 2021-03-31 包含Cas12i2变体多肽的组合物及其用途

Country Status (12)

Country Link
US (1) US20230332119A1 (cg-RX-API-DMAC7.html)
EP (1) EP4127154A1 (cg-RX-API-DMAC7.html)
JP (1) JP7881475B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230009379A (cg-RX-API-DMAC7.html)
CN (2) CN115698278B (cg-RX-API-DMAC7.html)
AU (1) AU2021249119A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019713A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177749A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022015170A2 (cg-RX-API-DMAC7.html)
IL (1) IL296791A (cg-RX-API-DMAC7.html)
MX (1) MX2022012189A (cg-RX-API-DMAC7.html)
WO (1) WO2021202800A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US20230193243A1 (en) * 2020-05-29 2023-06-22 Arbor Biotechnologies, Inc. Compositions comprising a cas12i2 polypeptide and uses thereof
EP4237557A1 (en) * 2020-10-30 2023-09-06 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting pdcd1 and uses thereof
TW202246497A (zh) * 2021-01-20 2022-12-01 美商阿伯生物技術公司 Cas12i2融合分子及其用途
AU2022284804A1 (en) * 2021-06-01 2023-12-07 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
KR20240034746A (ko) 2021-06-04 2024-03-14 아버 바이오테크놀로지스, 인크. 하이드록시산 산화효소 1(hao1)을 표적으로 하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도
WO2022256655A2 (en) 2021-06-04 2022-12-08 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting lactate dehydrogenase a (ldha) and uses thereof
US20220396782A1 (en) 2021-06-04 2022-12-15 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting transthyretin (ttr) and uses thereof
KR20240052763A (ko) * 2021-08-11 2024-04-23 아버 바이오테크놀로지스, 인크. 스타스민 2 (stmn2)를 표적화하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도
WO2023018856A1 (en) 2021-08-11 2023-02-16 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting polypyrimidine tract binding protein 1 (ptbp1) and uses thereof
WO2023034475A1 (en) 2021-09-01 2023-03-09 Arbor Biotechnologies, Inc. Cells modified by a cas12i polypeptide
EP4399293A4 (en) * 2021-09-10 2025-10-15 Arbor Biotechnologies Inc COMPOSITIONS COMPRISING A CAS12I POLYPEPTIDE AND USES THEREOF
AU2022382751A1 (en) * 2021-11-02 2024-05-23 Huidagene Therapeutics (Singapore) Pte. Ltd. Novel crispr-cas12i systems and uses thereof
WO2023081377A2 (en) * 2021-11-05 2023-05-11 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting ciita and uses thereof
WO2023122433A1 (en) 2021-12-22 2023-06-29 Arbor Biotechnologies, Inc. Gene editing systems targeting hydroxyacid oxidase 1 (hao1) and lactate dehydrogenase a (ldha)
WO2023138685A1 (en) * 2022-01-24 2023-07-27 Huidagene Therapeutics Co., Ltd. Novel crispr-cas12i systems and uses thereof
EP4514954A4 (en) * 2022-04-25 2026-03-25 Huidagene Therapeutics Singapore Pte Ltd NEW CRISPR-CAS12I SYSTEMS AND THEIR USES
EP4627083A1 (en) 2022-11-30 2025-10-08 Arbor Biotechnologies, Inc. Reverse transcriptase-mediated genetic editing of transthyretin (ttr) and uses thereof
US20260232844A1 (en) 2023-02-15 2026-08-13 Arbor Biotechnologies, Inc. Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript
WO2025096594A2 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof
CN117431235A (zh) * 2023-11-06 2024-01-23 微光基因(苏州)有限公司 CRISPR-Cas系统及其应用
WO2025147604A1 (en) 2024-01-05 2025-07-10 Arbor Biotechnologies, Inc. Methods for treating primary hyperoxaluria via genetic editing of hydroxyacid oxidase 1
WO2025171210A1 (en) 2024-02-09 2025-08-14 Arbor Biotechnologies, Inc. Compositions and methods for gene editing via homology-mediated end joining
WO2026015832A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Reverse transcriptases and gene editing systems comprising such
WO2026015829A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Small reverse transcriptases and gene editing systems comprising such
CN120424908B (zh) * 2025-07-10 2025-09-12 南京农业大学 一种基于LAMP与CRISPR/Cas的检测方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024178144A1 (en) * 2023-02-22 2024-08-29 Prime Medicine, Inc. Methods and compositions for editing nucleotide sequences

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
WO2014204725A1 (en) * 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
CN111218447B (zh) 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
PL3765615T3 (pl) * 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna
EP3924479A4 (en) * 2019-02-13 2023-01-25 Beam Therapeutics, Inc. ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024178144A1 (en) * 2023-02-22 2024-08-29 Prime Medicine, Inc. Methods and compositions for editing nucleotide sequences

Also Published As

Publication number Publication date
KR20230009379A (ko) 2023-01-17
BR112022019713A2 (pt) 2022-12-20
WO2021202800A1 (en) 2021-10-07
IL296791A (en) 2022-11-01
JP7881475B2 (ja) 2026-06-29
CN121380024A (zh) 2026-01-23
CO2022015170A2 (es) 2022-11-08
CN115698278A (zh) 2023-02-03
MX2022012189A (es) 2023-01-05
US20230332119A1 (en) 2023-10-19
CA3177749A1 (en) 2021-10-07
AU2021249119A1 (en) 2022-10-20
EP4127154A1 (en) 2023-02-08
JP2023520504A (ja) 2023-05-17

Similar Documents

Publication Publication Date Title
CN121380024A (zh) 包含Cas12i2变体多肽的组合物及其用途
US20240174997A1 (en) Compositions comprising a variant polypeptide and uses thereof
US20240035010A1 (en) Compositions comprising a variant polypeptide and uses thereof
US20250290053A1 (en) Compositions comprising a crispr nuclease and uses thereof
US20240352434A1 (en) Compositions comprising a variant cas12i3 polypeptide and uses thereof
US11946045B2 (en) Compositions comprising a variant polypeptide and uses thereof
US11866746B2 (en) Compositions comprising a variant Cas12i4 polypeptide and uses thereof
WO2024020557A1 (en) Compositions comprising a variant nuclease and uses thereof
WO2022150608A1 (en) Compositions comprising a variant crispr nuclease polypeptide and uses thereof
EP4158020A2 (en) Compositions comprising a cas12i2 polypeptide and uses thereof
CN118019846A (zh) 包含crispr核酸酶的组合物及其用途
CN117136233A (zh) 包含变体Cas12i4多肽的组合物及其用途
CN117043326A (zh) 包含变体多肽的组合物及其用途
CN117295816A (zh) 包含变体多肽的组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant